As you can see above, ATNM has been in a fairly tight channel for the past 3 months.
After dropping to a low in the $.22 range yesterday, a level it hasn't seen in over 3 weeks, there was an immediate bounce back up.
Though only a slight bounce, it could be the start of an even bigger move back towards the top of the channel.
If it can push through levels of resistance in the low $.30+ range, watch out, we could see a runner take off!
ATNM has many positives going for the company and several other key catalysts that could see their stock's share price take off in 2020.
Here are the most important catalysts that you need to know:
ATNM Catalyst #1 - Multiple Analyst Reports/Price Targets
“We have revised our estimates to reflect these timeline expectations, but remain firmly impressed with Iomab-B’s safety, feasibility, and early efficacy findings in SIERRA and optimistic about the trial’s odds of a positive conclusion. Having reached this key checkpoint, the next potential SIERRA- related catalyst is likely to be safety and feasibility data (akin to what was presented at ASH 2018 for the first 25% of patients in SIERRA) for the first 50% of patients now enrolled, which may be reported at ASH this December, if not sooner.
Additionally, we hope to see confirmation of the standout effects of Iomab-B alone on pre-transplant blast counts among the 75 patients currently enrolled (potentially in 1H:20) as a follow-up to what was seen in the first 38 patients at ASCO last month."
The company maintained their "BUY" rating and moved their 12-month price target to $4.00/share.
At a price target of $4.00, JonesTrading is giving ATNM upwards of an approximate 1,566% potential upside from the stock's approximate $.24 current trading level.
William Blair & Co.
Analyst Andy Hsieh said, “Actinium’s lead asset, Iomab-B, is an antibody-radiation conjugate composed of an anti-CD45 antibody that is linked to radioisotope iodine-131. The compound is being investigated as a conditioning regimen prior to hematopoietic stem cell transplantation in the acute myeloid leukemia, or AML, setting. Conditioning regimens are responsible for eliminating residual cancer cells, removing healthy cells in the bone marrow so that donor stem cells can reside and thrive, and reducing the host immune activity to prevent tissue rejection, thereby optimizing the outcome for transplantation.
Stem cell transplantation is the only treatment for AML that could lead to long-term remission; however, given the toxicity of conditioning regimens, the procedure is typically performed only on young and fit patients. Combining the ability to home in on a tumor-specific marker and the potency of radiotherapy, targeted conditioning, such as Iomab-B, could improve on the current standard-of-care conditioning regimens.
Based on our estimates, the targeted conditioning market is roughly $600Mn in the United States and Europe, and positive results could fuel material growth in its clinical usage. Actinium is also making progress on several pipeline initiatives that could provide investors with multiple shots on goal.”
Zacks Investment Research + Maxim Group
ATNM has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Actinium Pharmaceuticals to a "Strong Buy" on January 13th, causing a massive volume breakout.
Maxim Group restated a “buy” rating and issued a $1.50 price objective on shares of Actinium Pharmaceuticals in a research report.
With a $1.50 price target, Maxim Group is giving ATNM upside potential of approximately 525% from its current approximate trading level of $.24.
ATNM Catalyst #2 - Institutional Investing / Bullish Hedge Funds
At the end of the third quarter in 2019, a total of 6 of the hedge funds tracked by Insider Monkey held long positions in this stock. On the other hand, there were a total of 4 hedge funds with a bullish position in ATNM a year ago.
More specifically, Sabby Capital was the largest shareholder of Actinium Pharmaceuticals Inc, with a stake worth $2Mn reported as of the end of September. Trailing Sabby Capital was Sio Capital, which amassed a stake valued at $1.4Mn. Endurant Capital Management, Renaissance Technologies, and Citadel Investment Group were also very fond of the stock, becoming one of the largest hedge fund holders of the company.
In terms of the portfolio weights assigned to each position Sabby Capital allocated the biggest weight to Actinium Pharmaceuticals Inc, around 1.09% of its 13F portfolio. Sio Capital is also relatively very bullish on the stock, dishing out 0.44% of its 13F equity portfolio to ATNM.